Hing (Asafoetida) for Bloating Relief

Research suggests that asafoetida (hing) has meaningful support for bloating relief across multiple study types, including two randomized controlled trials, animal studies, and several reviews of traditional and pharmacological evidence. A 2025 RCT found significant bloating improvement in functional dyspepsia patients, and a double-blind placebo-controlled trial reported that roughly 58% of participants experienced bloating relief with an asafoetida-based formulation. Studies indicate the proposed mechanisms include carminative, antispasmodic, and digestive enzyme-enhancing properties, with laboratory research on isolated rat tissue and a rat model of delayed gastric emptying providing biological plausibility for these effects. The overall body of evidence points in a consistently supportive direction, though it is worth noting that several studies used proprietary formulations rather than asafoetida alone, sample sizes in the clinical trials were generally modest, and independent large-scale replication remains limited.